Hypertension and chronic kidney disease are inextricably linked.
Introduction
Hypertension and chronic kidney disease are intersecting diseases with enormous economic burdens. The design and implementation of genotype-guided care in clinics enables providers to identify drug-gene interactions to inform medication selection, improve treatment efficacy, and reduce adverse events and their associated medical costs. Genetic predictors of chronic kidney disease (CKD) progression may augment standard clinical prediction models, impacting prognosis, medication selection, dialysis initiation, and renal transplant organ allocation. We have designed a genotyping test to detect 72 genetic variants in drug metabolizing enzymes and other genes to aid providers in the management of hypertension, chronic kidney disease, and other related conditions. This communication focuses on the analytical validity of the renal precision medicine assay, including CLIA validation with the assessment of precision and accuracy, analytical sensitivity and specificity, variant reporting strategy, and confirmation of positive reference materials through sequencing. Our goal is to facilitate implementation for future investigators and health systems. A detailed discussion of each variant's clinical validity extends beyond the scope of this manuscript; however, content examples are provided in order to convey context and purpose.
Variant Selection
Variants in the renal precision medicine assay were selected after balancing their significance, effect size, minor allele frequency, and level of evidence. When applicable, drug-gene phenotypes were utilized from the Pharmacogene Variation Consortium (PharmVar), the Food and Drug Administration (FDA) drug label, Clinical Pharmacogenomics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG) [1, 2] . The three groups of variants represented include predictors of 1) antihypertensive drug response, 2) drug response relevant to immunosuppression or cardiovascular disease, and 3) CKD progression. Antihypertensive pharmacogenomic variants were included for metoprolol (CYP2D6), other beta-blockers (GRK4, ADRB1), hydralazine (NAT2), losartan (CYP2C9), amlodipine (F7), thiazide diuretics (YEATS4, FGF5/SH2B3/EBF1), diuretics (NEDD4L), angiotensin-converting-enzyme inhibitors (F7), and angiotensin II receptor blockers (NPHS1) ( Table 1) [3] [4] [5] [6] [7] [8] [9] [10] [11] . The clinical validity of these variants has been previously reviewed and their associated levels of evidence vary [12, 13] . For example, CYP2D6-guided dosing of metoprolol has been recommended by the DPWG.
The FDA drug labels of hydralazine and losartan include NAT2 and CYP2C9 metabolizer status, respectively, as predictors of response. This assay employs genotype as a surrogate to establish metabolizer status for these drugs. Other antihypertensive response predictors included in the assay have lower levels of evidence for implementation. Although they have been replicated in clinical trials, their clinical use is still considered investigational.
A second group of pharmacogenomic variants found in the CYP3A4 and CYP3A5, TPMT, SLCO1B1, CYP2C9, VKORC1, and CYP2C19 genes have been widely studied with genotype-guided dosing recommendations from CPIC and DPWG for drugs such as tacrolimus, azathioprine, simvastatin, warfarin, and clopidogrel (Table 1) [14] [15] [16] [17] [18] . The immunosuppressant drug-gene pairs were selected to aid in glomerulonephritis and posttransplant care. The cardiovascular drug-gene pairs were included due to the preponderance of cardiovascular disease in patients with CKD.
A third group of variants have been identified as predictors of CKD progression (Table 2 ) [19] [20] [21] [22] . Genes associated with progression were identified from large genome-wide association studies or prospective clinical cohorts and trials such as the Chronic Renal Insufficiency Cohort and African American Study of Kidney Disease and Hypertension [20] . These genes include APOL1, relevant to individuals with African ancestry, as well as other genes identified from African-American, Asian and Caucasian populations, with or without diabetes mellitus. Their clinical validity has been reviewed elsewhere [23] .
Variant Reporting
When feasible, genetic nomenclature and allele reporting was utilized from PharmVar and CPIC. Drug-gene pairs with lower levels of evidence often lack a consensus allelic structure. As a result, the ADRB1, FGF5/SH2B3/EBF1, and GRK4 genes each include a multi-variant model to predict efficacy that is summarized by copies of amino acids or efficacy alleles. The APOL1 gene is comprised of the *G1 (G and GM) and *G2 variant alleles. The *G1 allele is described as two missense variants and the *G2 allele is a 6 base pair deletion that is in high linkage disequilibrium with a single nucleotide polymorphism marker used in this assay. These variants are reported based on quantity of risk alleles. All other variants were classified based on the nucleotides detected. The effects of some variants were only studied or found to be significantly associated with phenotypes in certain populations. As such, some variants are only relevant in a single ethnicity or in individuals without diabetes. This distinction is made in the relevant population column of Table 1 and 2.
Genotyping Assay Validation
We designed a custom OpenArray in which Taqman allele discrimination was used for genotyping analysis for our selected variants. DNA samples were amplified in singlicate by real-time PCR on the LifeTech QuantStudio 12K Flex (software v1.2.2; Grand Island, NY) using commercially available reagents for the custom designed OpenArray according to the user manual (Life Technologies, Grand Island, NY). DNA samples used for analytical validation were obtained from the Coriell Cell Repository (Camden, NJ) and Icahn School of Medicine at Mount Sinai (New York, NY) [24] . In this paper, we describe the CLIA validation process for the variants provided in Supplemental Table 1 Since there were no known reference materials for most variants, selected DNA samples were Sanger sequenced with custom designed primers (Integrated DNA Technologies, Coralville, IA) for accuracy studies (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/FPC/B331). PCR amplification was performed on the GeneAmp PCR System 2720 (Applied Biosystems). The targeted gene region was amplified using custom primers and PCR SuperMix (Invitrogen, Carlsbad, CA) at the following PCR amplification conditions: 94°C for 2 minutes, 35 cycles at 94°C for 15 seconds, 56°C for 30 seconds, 72°C for 1 minute and a final extension step at 72°C for 7 minutes. PCR purification was performed using a QIAquick PCR Purification Kit (Qiagen, Valencia, CA) according to the user manual. Samples were prepared for sequencing using 10 μL of purified PCR amplicon (50 ng total) and 2 μL of the sequencing primer [1.7 μM] and Sanger sequenced by ACGT Inc. (Germantown, MD). For ADRB1, reference materials that were previously whole genome sequenced in the 1000 Genomes Project were obtained and genotyped. Variant information from the project was retrieved from https://www.ncbi.nlm.nih.gov/variation/ tools/1000genomes/ to confirm the accuracy of the ADRB1 analytical validation study.
The sequencing results were compared to the array genotyping results and were completely concordant for 100% accuracy. Based on the orthogonal method (e.g. DNA sequencing), the variant and reference allele used to calculate the assay's analytical sensitivity and specificity (Table 3 and Supplemental Table 2 , Supplemental Digital Content 2, http:// links.lww.com/FPC/B332 ). The analytical sensitivity was 100% for the detection of variant alleles, with no reported false negatives. The analytical specificity was 100% for detection of reference alleles, with no false positive results reported (note at the 95th percentile, the confidence intervals varied based on variant frequencies). DNA samples were also used to assess intra-and inter-assay variation. In all, 14 samples obtained from Icahn School of Medicine at Mount Sinai were included in intra-assay validation. There were 18 samples included in the inter-assay validation which were comprised of the 14 Icahn School of Medicine at Mount Sinai samples plus four additional Coriell cell line samples that included the less frequent genotypes (NA07357, NA10847, NA18524, NA18563). In order to find these less frequent genotypes needed for validation, 189 total Coriell samples were genotyped successfully. These results are included in Supplemental Table 2 , Supplemental Digital Content 2, http://links.lww.com/FPC/B332, to serve as reference materials for laboratories that may validate the same variants. The intra-(within) assay variation studies showed that all three replicates of the 14 samples ran on the same plate, were concordant with expected results. The inter-(between) assay variation studies showed that the 18 samples consistently yielded the same result across three separate runs. The stability had been previously established for the following conditions: DNA isolated from whole blood at room temperature after 1 week, refrigerated for 2 weeks, and frozen for 4 weeks, saliva after 5 years at room temperature, frozen indefinitely, and extracted DNA refrigerated and frozen for 5 and 15 years, respectively.
Implementation
The implementation of genetic testing to aid in personalized therapy has become more widespread. Applications for the variants detected with this assay may extend beyond the clinical care of individuals with hypertension and CKD as illustrated by the implementation efforts of networks like the Implementing Genomics in Practice (IGNITE) and APOL1 Long-Term Kidney Transplantation Outcomes (APOLLO) consortia. Further pragmatic trials are needed to determine clinical validity and utility. Understanding the underlying genetic architecture which predisposes an individual to develop chronic kidney disease allows us to build upon existing functional CKD classifications, which are presently based on estimate glomerular filtration rates and proteinuria. The implementation of genetic testing into clinical practice has the potential to augment drug selection, dose adjustment, improve the classification of CKD in patients, and more accurately predict the risk of progression. This testing serves as a complement to, not a replacement for, effective clinical practice.
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